Physician profile
Richard L Sample
NPI 1497713200
$799.53
in general payments reported to CMS, 2019-2025
11 companies · $68.73 in 2025
The $68.73 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.79 · 2020: $25.79 · 2021: $117 · 2022: $111 · 2023: $387 · 2024: $49.10 · 2025: $68.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $274 · Food and Beverage: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $274.02 |
| Food and Beverage | $230.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $274.02 | 2023 | Ethicon, Dermabond |
| Janssen Pharmaceuticals, INC | $115.34 | 2020-2023 | Xarelto |
| Abbvie INC. | $107.15 | 2021-2023 | Dalvance |
| Melinta Therapeutics, LLC | $100.94 | 2022-2025 | Orbactiv, Kimyrsa |
| Pfizer INC. | $49.63 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $35.34 | 2022-2023 | Andexxa |
| Purdue Pharma L.P. | $33.90 | 2024-2025 | Nalmefene Hydrochloride |
| E.R. Squibb & Sons, L.L.C. | $25.42 | 2020-2021 | |
| Portola Pharmaceuticals, LLC | $24.86 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.52 | 2025 | Xifaxan |
| Grifols USA, LLC | $15.41 | 2024 | Hyperrab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Sample listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.